TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05797207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-assisted Fecal Microbiome Testing
Description: Next-generation sequencing of fecal samples and artificial intelligence analysis of test results

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy procedure
Study: NCT04901169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Study: NCT06344377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Betaine supplemented for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation for 8 weeks
Study: NCT06156267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab is a programmed death-ligand 1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA tumor vaccines
Description: neoantigen personalized mRNA vaccines
Study: NCT05348915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclacumab
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Study: NCT05206331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast enhanced mammography
Description: Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Media (ICM)
Description: standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
Study: NCT04730375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
Study: NCT04942210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (produced on serum-free Vero cells)
Description: Powder and diluent for suspension for injection Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow fever vaccine
Description: Powder and diluent for suspension for injection Subcutaneous injection
Study: NCT06737042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: GLP-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Active Comparator
Study: NCT06737081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951 tablets 4mg
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT04901169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Study: NCT05472311

Intervention type: OTHER
Group type: OTHER
Intervention: Thermal Ablation
Description: Thermal ablation is based on local heating (around 100 degrees centigrade), applied for 20 to 60 seconds to destroy abnormal tissue by burning and inducing necrosis of pre-cancer and surrounding tissue. It has been used in by gynecological surgery for over 50 years, proven safe and easy to use by middle level health care providers in primary care settings.
Study: NCT06558695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane was managed for maintenance of the general anestesia during spinal surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: TIVA was managed for maintenance of the general anesthesia during spinal surgeries
Study: NCT05507580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet
Study: NCT06562517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital training module
Description: The intervention is a 24/7 accessible educational website for pediatric oncology nurses, based on the EONS Cancer Nursing Education Framework. It features five validated training modules, enhanced with visual and auditory materials such as videos and infographics. Nurses will receive login credentials, allowing them to access the platform and participate in the training. Each module ends with a 20-question test, requiring a score of 60 to advance. A support line enables nurses to ask questions directly to researchers. Successful completion of each module earns a certificate. The website will be piloted with 15 nurses, and feedback will be used to refine its design and content.
Study: NCT06560593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ5082
Description: single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ5082
Description: single ascending dose, randomized, double-blind study，with 8 dose groups preset. The first cohort will be the sentinel group, consisted of 2 subjects receiving NTQ5082 capsules. The remaining cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: multiple ascending dose, randomized, double-blind study，with 3 dose groups preset. All cohorts required 8 subjects each, with 6 receiving NTQ5082 capsules and 2 receiving placebo.
Study: NCT05594693

Intervention type: OTHER
Intervention: Questionnaire
Description: Electronic self-report questionnaires before and after integrative interventions, and monthly.

Intervention type: OTHER
Intervention: Physical Exam
Description: Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
Study: NCT06332170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/ Carboplatin
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/ Carboplatin
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg once daily (QD) orally
Study: NCT05456594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a conventional bra (bra condition #1).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bounceless bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bounceless bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Bounceless bra (bra condition #2a).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shefit bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shefit bra
Description: This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing breast motion while using a provided Shefit bra (bra condition #2b).
Study: NCT06469645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.
Study: NCT05226533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscular injection of DWRX2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscular injection of DWRX2003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection of placebo
Study: NCT06737081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951 tablets 5mg
Description: initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT06737250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2P -> RP
Description: Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14
Study: NCT06737679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online.
Study: NCT06075940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGNITUDE BRS
Description: Treatment with the MAGNITUDE Scaffold
Study: NCT04885738

Intervention type: OTHER
Intervention: no intervention
Description: For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD.

Intervention type: OTHER
Intervention: no intervention
Description: For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD.

Intervention type: OTHER
Intervention: no intervention
Description: For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD.
Study: NCT06737237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical plexus block
Description: local anesthetic (10ml of bupivacaine 5mg/ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration Analgesia (LIA)
Description: local anesthetic (20ml of bupivacaine 2.5mg/ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical plexus block
Description: placebo (10ml of 0.9% sodium chloride)
Study: NCT04054427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD L GF consisting of hydrophobic material
Study: NCT05089201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted interaction
Description: A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conversational control
Description: A handler alone will visit participants without a dog for approximately 20 minutes on 3 consecutive days during their inpatient hospital stay
Study: NCT05269069

Intervention type: OTHER
Intervention: Assessment of body composition, bone mineral density and bone marrow adiposity.
Description: DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)

Intervention type: OTHER
Intervention: Assessment of body composition, bone mineral density and bone marrow adiposity.
Description: DXA for body composition and bone mineral density, MRI for bone marrow adiposity and blood tests (leptine, CTX, P1NP)
Study: NCT05474027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance of Deliberate Hypotensive Anesthesia
Description: The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION
Description: 1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
Study: NCT06737237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration Analgesia (LIA)
Description: placebo (20ml of 0.9% sodium chloride)
Study: NCT06737965

Intervention type: OTHER
Intervention: Medical abortion
Description: Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory.
Study: NCT04844190

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EndoFLIP
Description: During pre-G-POEM upper endoscopy, an EndoLIP catheter will be inserted through the patient's mouth into the stomach and across the pylorus. Once results of EndoFLIP are obtained, the catheter will be removed (5 minutes).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Antroduodenal Manometry
Description: Following removal the EndoFLIP catheter, a manometry catheter will then be placed through the nose and advanced across the pylorus. Once catheter positioning is confirmed on endoscopy, the endoscope will be withdrawn. The manometry catheter will be taped to the nose and sedation stopped. The patient will be brought to the recovery area where they will wake-up with the catheter in place. In a private recovery room, the patient will have the catheter in place (no positioning or movement restrictions). When pyloric spasms are documented (0.5-4 hours), they will be given a standard small meal (water, toast/bread). Once motility is assessed with eating, the manometry catheter will be removed.
Study: NCT06244186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is provided by TCI CO., Ltd.
Study: NCT06737965

Intervention type: OTHER
Intervention: Medical abortion
Description: Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory.

Intervention type: OTHER
Intervention: Foetopathology exam
Description: Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution.

Intervention type: OTHER
Intervention: Foetopathology exam
Description: Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution.

Intervention type: OTHER
Intervention: Outcomes mesurement
Description: * From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone.
Study: NCT05508152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wound irrigation with amoxicillin-clavulanate in saline solution
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Wound irrigation with a saline solution
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes.
Study: NCT06466733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the middle meningeal artery
Description: Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Evacuation via burr hole or craniotomy
Description: The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.